MedPath

MetaDerm Cream in Atopic Dermatitis

Not Applicable
Conditions
Health Condition 1: null- moderate to severe Atopic Dermatitis
Registration Number
CTRI/2016/03/006782
Lead Sponsor
Haus Bioceuticals Inc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
48
Inclusion Criteria

•Moderate to severe atopic dermatitis as determined by Physicianâ??s Global Assessment (PGA > 3.

•Males and females, age 12 - 65 years old inclusive.

Exclusion Criteria

•Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 2 weeks.

•Currently or has been diagnosed or treated for cancer in the past 5 years.

•Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).

•Has a known hypersensitivity to any corticosteroid creams.

•Has any active infections or has used antibiotics in the past 7 days.

•Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring,excessive hair growth or acne).

•Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.

•Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.

•Is an employee of the sponsor company or clinical testing site.

•Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.

•Is currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention).

•Has a history of keloid formation following skin injury.

•Is routinely taking anti-coagulant medications (i.e. Plavix,Coumadin, warfarin, heparin, etc.)

•Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath